CA2246227A1 - Composition for the transfection of higher eucaryotic cells - Google Patents
Composition for the transfection of higher eucaryotic cells Download PDFInfo
- Publication number
- CA2246227A1 CA2246227A1 CA002246227A CA2246227A CA2246227A1 CA 2246227 A1 CA2246227 A1 CA 2246227A1 CA 002246227 A CA002246227 A CA 002246227A CA 2246227 A CA2246227 A CA 2246227A CA 2246227 A1 CA2246227 A1 CA 2246227A1
- Authority
- CA
- Canada
- Prior art keywords
- egla
- composition according
- peptide
- transfection
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19605548A DE19605548A1 (de) | 1996-02-15 | 1996-02-15 | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| DE19605548.2 | 1996-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2246227A1 true CA2246227A1 (en) | 1997-08-21 |
Family
ID=7785445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002246227A Abandoned CA2246227A1 (en) | 1996-02-15 | 1997-02-13 | Composition for the transfection of higher eucaryotic cells |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0900281A1 (enExample) |
| JP (1) | JP2000504579A (enExample) |
| CA (1) | CA2246227A1 (enExample) |
| DE (1) | DE19605548A1 (enExample) |
| MX (1) | MX9805507A (enExample) |
| WO (1) | WO1997030170A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766705B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics | Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| GB9918670D0 (en) | 1999-08-06 | 1999-10-13 | Celltech Therapeutics Ltd | Biological product |
| GB0120022D0 (en) * | 2001-08-16 | 2001-10-10 | Photobiotics Ltd | Conjugate |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| HUE061068T2 (hu) | 2010-08-31 | 2023-05-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
| EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| WO2017024319A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| JP7045378B2 (ja) | 2016-09-01 | 2022-03-31 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ最適化ＣＡＲ Ｔ細胞 |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| US20240216509A1 (en) | 2018-05-07 | 2024-07-04 | Children's Hospital Medical Center | Chimeric polypeptides, nucleic acid molecules, cells, and related methods |
| EP3957325A4 (en) | 2019-04-19 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE |
| KR20220017430A (ko) | 2019-06-05 | 2022-02-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 절단 부위 결합 분자 |
| MX2023001120A (es) | 2020-07-31 | 2023-02-22 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica que comprende una celula que expresa un receptor quimerico. |
| EP4310188A1 (en) | 2021-03-17 | 2024-01-24 | Daiichi Sankyo Company, Limited | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody |
| WO2022214887A1 (en) | 2021-04-08 | 2022-10-13 | Phosphogam, Llc | Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells |
| JPWO2024150525A1 (enExample) | 2023-01-12 | 2024-07-18 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| FR2714830B1 (fr) * | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| EP0874910A4 (en) * | 1995-06-07 | 1999-04-21 | Life Technologies Inc | ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES |
| IL115199A (en) * | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
-
1996
- 1996-02-15 DE DE19605548A patent/DE19605548A1/de not_active Ceased
-
1997
- 1997-02-13 WO PCT/EP1997/000649 patent/WO1997030170A1/de not_active Ceased
- 1997-02-13 CA CA002246227A patent/CA2246227A1/en not_active Abandoned
- 1997-02-13 EP EP97904426A patent/EP0900281A1/de not_active Withdrawn
- 1997-02-13 JP JP9528984A patent/JP2000504579A/ja not_active Abandoned
-
1998
- 1998-07-07 MX MX9805507A patent/MX9805507A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE19605548A1 (de) | 1997-09-04 |
| WO1997030170A1 (de) | 1997-08-21 |
| EP0900281A1 (de) | 1999-03-10 |
| JP2000504579A (ja) | 2000-04-18 |
| MX9805507A (es) | 1998-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2246227A1 (en) | Composition for the transfection of higher eucaryotic cells | |
| AU747803B2 (en) | Novel compositions for the delivery of negatively charged molecules | |
| US8058068B2 (en) | Peptide-enhanced transfections | |
| US7772201B2 (en) | Highly branched HK peptides as effective carriers of siRNA | |
| Martin et al. | Peptide-guided gene delivery | |
| JP4265699B2 (ja) | ペプチドによって増強されるトランスフェクション | |
| ES2200051T3 (es) | Metodos y composiciones para la lipidizacion de moleculas hidrofilas. | |
| US7553830B2 (en) | Compositions for the delivery of negatively charged molecules | |
| SK281543B6 (sk) | Farmaceutická kompozícia na transfekciu nukleovej kyseliny | |
| US20030165567A1 (en) | Histidine copolymer and methods for using same | |
| JPH11506935A (ja) | ペプチド増強カチオン脂質トランスフェクション | |
| SK282173B6 (sk) | Lipopolyamíny ako transfekčné činidlá, spôsob ich prípravy a farmaceutické kompozície s ich obsahom | |
| RU2739987C2 (ru) | Множественные олигонуклеотидные фрагменты на пептидном носителе | |
| US9399016B2 (en) | Materials and complexes for the delivery of biologically-active materials to cells | |
| US6281371B1 (en) | Lipopolyamines, and the preparation and use thereof | |
| AU720697B2 (en) | Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof | |
| JP2019510083A (ja) | 生物学的活性物質の細胞への送達のための脂質および複合体 | |
| WO1999065461A3 (en) | Cationic amphiphile micellar complexes | |
| US7297712B2 (en) | Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment | |
| WO2024110492A9 (en) | Novel carriers for nucleic acid and/or protein delivery | |
| CN120737148A (zh) | 经由穿膜肽进行非共价修饰脂质纳米颗粒缀合物及用途 | |
| Chaum et al. | LIPID MEDIATED GENE TRANSFER LIPID MEDIATED GENE TRANSFER | |
| EP1724254A2 (en) | Novel compositions for the delivery of negatively charged molecules | |
| MXPA97006016A (en) | Composition containing nucleic acids, preparation and use | |
| KR20180010235A (ko) | 생물학적으로 절단가능한 테트라펩티드 연결제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |